Gene · 84444
Papers2,742
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
101 to 120 of 2,742
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Dual targeting of EZH2 and DOT1L in DLBCL. | Blood | 2025 | 40244641 | PubTator, text mining | PubMed |
| Discovery of the first-in-class DOT1L PROTAC degrader. | Eur J Med Chem | 2025 | 40186895 | PubTator, text mining | PubMed |
| Exploring the Therapeutic Potential of the DOT1L Inhibitor EPZ004777 Using Bioinformatics and Molecular Docking Approaches in Acute Myeloid Leukemia. | Curr Issues Mol Biol | 2025 | 40136427 | PubTator, text mining | PubMed |
| Significant correlation between serum DOTL1 levels and pain intensity, sensitivity, and psychological distress in women with fibromyalgia. | Medicine (Baltimore) | 2025 | 40128062 | PubTator, text mining | PubMed |
| Particle uptake by macrophages triggers bifurcated transcriptional pathways that differentially regulate inflammation and lysosomal gene expression. | Immunity | 2025 | 40118070 | PubTator, text mining | PubMed |
| Study on DNA Damage Gene in Spermatogonial Stem Cells from Idiopathic Nonobstructive Azoospermia: A Bioinformatics Investigation Based on scRNA-seq Data. | Cytogenet Genome Res | 2025 | 40101697 | PubTator, text mining | PubMed |
| TET2 deficiency increases the competitive advantage of hematopoietic stem and progenitor cells through upregulation of thrombopoietin receptor signaling. | Nat Commun | 2025 | 40064887 | PubTator, text mining | PubMed |
| Design, synthesis and evaluation of pyrimidinobenzylamide and pyrimidinothiophenamide derivatives as inhibitors of DOT1L and related epigenetic targets DNMT3a, PRMT4 and other HMTs. | RSC Med Chem | 2025 | 40061000 | PubTator, text mining | PubMed |
| Chromatin Organization Governs Transcriptional Response and Plasticity of Cancer Stem Cells. | Adv Sci (Weinh) | 2025 | 40051293 | PubTator, text mining | PubMed |
| Synergistic antitumor effect of combined EZH2 and DOT1L inhibition in B-cell lymphoma. | Blood | 2025 | 40009485 | PubTator, text mining | PubMed |
| DOT1L in neural development and neurological and psychotic disorders. | Neurochem Int | 2025 | 39993657 | PubTator, text mining | PubMed |
| Transcription-replication conflicts drive R-loop-dependent nucleosome eviction and require DOT1L activity for transcription recovery. | Nucleic Acids Res | 2025 | 39988315 | PubTator, text mining | PubMed |
| DOT1L Regulates Cellular Senescence during the Progression from Acute Kidney Injury to Chronic Kidney Disease via the microRNA-222-5p/WNT9B Signaling Pathway. | Am J Nephrol | 2025 | 39938490 | PubTator, text mining | PubMed |
| Chromatin environment-dependent effects of DOT1L on gene expression in male germ cells. | Commun Biol | 2025 | 39875559 | PubTator, text mining | PubMed |
| Peptide design to control protein-protein interactions. | Chem Soc Rev | 2025 | 39817557 | PubTator, text mining | PubMed |
| Targeting DOT1L and EZH2 synergizes in breaking the germinal center identity of diffuse large B-cell lymphoma. | Blood | 2025 | 39792929 | PubTator, text mining | PubMed |
| DOT1L Mediates Stem Cell Maintenance and Represents a Therapeutic Vulnerability in Cancer. | Cancer Res | 2025 | 39700409 | PubTator, text mining | PubMed |
| Antitumor activity of selenopsammaplin A analog (SPA-10091-HCl) via histone methyltransferase DOT1L degradation and apoptosis induction in castration-resistant prostate cancer cells. | Eur J Pharm Sci | 2025 | 39689820 | PubTator, text mining | PubMed |
| CRISPRepi: a multi-omic atlas for CRISPR-based epigenome editing. | Nucleic Acids Res | 2025 | 39530233 | PubTator, text mining | PubMed |
| Corrigendum to "Hesperetin promotes DOT1L degradation and reduces histone H3K79 methylation to inhibit gastric cancer metastasis" [Phytomedicine 84 (2021) 153499/PMID: 33667841]. | Phytomedicine | 2025 | 39304354 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/84444/papers?page=6